These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7553959)

  • 1. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
    Han B; Jia Y; Zhou M
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to the treatment of malignant effusion.
    Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
    Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
    Kan N
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
    Li D; Zhang X; Song Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study].
    Thiounn N; Mathiot C; Flam T; Tartour E; Peyret C; Joyeux I; Abecassis JP; Zerbib M; Fridman WH; Debré B
    J Urol (Paris); 1994; 100(4):185-8. PubMed ID: 7868930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
    Kan N
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
    Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
    J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
    Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
    Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
    Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
    Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
    Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
    Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.